Lido Advisors
NRXP icon

Lido Advisors’s NRX Pharmaceuticals NRXP Stock Holding History

Lido Advisors’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,300
Closed -$3.38K – 1405
2023
Q3 		$3.38K Buy
+1,300
New +$4.32K ﹤0.01% 1205

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
OWMIAS
One Wealth Management Investment & Advisory Services Miami Beach, Florida $95.3M AUM 25.31% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lido Advisors's NRXP Position: Q4 2023 in Review

Lido Advisors sold out of NRX Pharmaceuticals (NRXP) in Q4 2023, closing a stake of 1,300 shares — an estimated $3.38K sold.

Lido Advisors first reported a position in NRXP in Q3 2023 and held it in 1 quarter. The position peaked at $3.38K in Q3 2023. 30 funds tracked by Wall St. Rank hold NRXP as of Q4 2023.

  • Lido Advisors reported no remaining NRX Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Lido Advisors sold 1,300 NRX Pharmaceuticals shares in Q4 2023, an estimated $3.38K.
  • Lido Advisors first reported a position in NRX Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Lido Advisors's NRX Pharmaceuticals position peaked at $3.38K in Q3 2023.
  • 30 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q4 2023.

Based on Lido Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.